The fast track approval route has been mentioned by the company several times. So I agree this is a goal. I see some of the funds from the CR are to be used to run an expansion trial off the phase 1 results. This will be to gain more data to support fast track approval.
So I think the timeline for the phase 2b/3 trial will be strechted a bit beyound 2023.
Another company i am invested in has just attempted to raise $36 million to run a fast track approval trial. That trial will last 12 months with 108 patients. As an example.
The fast track approval route has been mentioned by the company...
-
- There are more pages in this discussion • 179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
0.001(3.13%) |
Mkt cap ! $14.63M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $1.242K | 76.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 2409370 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 718819 | 5 |
View Market Depth
| Last trade - 12.25pm 27/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |